Last reviewed · How we verify
ABT-450/ritonavir
ABT-450/ritonavir is a Hepatitis C virus NS3/4A protease inhibitor Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 3 development for Chronic hepatitis C virus infection (genotype 1 and 4). Also known as: ABT-450 also known as paritaprevir.
ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels.
ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels. Used for Chronic hepatitis C virus infection (genotype 1 and 4).
At a glance
| Generic name | ABT-450/ritonavir |
|---|---|
| Also known as | ABT-450 also known as paritaprevir |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Hepatitis C virus NS3/4A protease inhibitor |
| Target | HCV NS3/4A serine protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
ABT-450 directly inhibits the NS3/4A serine protease of hepatitis C virus, preventing the cleavage of viral polyproteins necessary for viral replication. Ritonavir, a CYP3A4 inhibitor, is co-administered as a pharmacokinetic booster to elevate and maintain therapeutic ABT-450 concentrations. This combination was developed as part of all-oral, interferon-free HCV treatment regimens.
Approved indications
- Chronic hepatitis C virus infection (genotype 1 and 4)
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Elevated bilirubin
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
- Study of Oral Treatments for Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-450/ritonavir CI brief — competitive landscape report
- ABT-450/ritonavir updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI
Frequently asked questions about ABT-450/ritonavir
What is ABT-450/ritonavir?
How does ABT-450/ritonavir work?
What is ABT-450/ritonavir used for?
Who makes ABT-450/ritonavir?
Is ABT-450/ritonavir also known as anything else?
What drug class is ABT-450/ritonavir in?
What development phase is ABT-450/ritonavir in?
What are the side effects of ABT-450/ritonavir?
What does ABT-450/ritonavir target?
Related
- Drug class: All Hepatitis C virus NS3/4A protease inhibitor drugs
- Target: All drugs targeting HCV NS3/4A serine protease
- Manufacturer: AbbVie (prior sponsor, Abbott) — full pipeline
- Therapeutic area: All drugs in Virology / Hepatology
- Indication: Drugs for Chronic hepatitis C virus infection (genotype 1 and 4)
- Also known as: ABT-450 also known as paritaprevir
- Compare: ABT-450/ritonavir vs similar drugs
- Pricing: ABT-450/ritonavir cost, discount & access